Trial Profile

Ticagrelor vs. clopidogrel in patients undergoing implantation of paclitaxel-eluting stents in the femoropopliteal district: a randomized, nested pilot study using Frequency-Domain Optical Coherence Tomography (FD-OCT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ticagrelor (Primary) ; Clopidogrel
Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Peripheral ischaemia
Focus Therapeutic Use

29 Aug 2018 Primary endpoint (Net percentage volume obstruction assessed by Frequency-Domain -Optical Coherence Tomography) has not been met, according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
29 Aug 2018 Status changed from recruiting to completed according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com